UNIVERSITY OF SYDNEY

🇦🇺Australia
Ownership
-
Established
1850-01-01
Employees
-
Market Cap
-
Website
https://www.sydney.edu.au/
news.med.miami.edu
·

Desai Sethi Research Team Identifies How to Reverse the Genetics of Poor Prostate Cancer

Desai Sethi Urology Institute researchers found that prostate cancer patients with the adrenal-permissive HSD3B1 allele had better survival outcomes when treated with ADT plus enzalutamide or ADT plus nonsteroidal antiandrogen, reversing poor genetic outcomes.
theguardian.com
·

Fifteen architecture firms shortlisted for NSW competition aimed at alleviating housing crisis

15 architecture firms from Australia and overseas compete to design homes for 5 Sydney sites to alleviate NSW housing crisis. The NSW government's pattern book design competition aims to fast-track construction by pre-approving selected designs. Five winners will build low- and medium-rise designs across five sites, including Sydney Olympic Park. The winning designs will be publicly available next year, with fast-track benefits.
theguardian.com
·

Australian pregnancy drugs shortage sparks call to include pregnant women in clinical trials

Pregnancy drug shortages in Australia stem from old, less profitable medications being discontinued due to manufacturing disruptions post-pandemic. Experts call for a government body to oversee critical medication registration, import, and production, independent of profit motives, to ensure pregnant women have access to necessary treatments.
drugs.com
·

Depressed Adolescents Twice as Likely to Take Up Vaping

Depressed Australian adolescents have double the risk of vaping, with stress levels linked to vaping rates. No link found between anxiety and vaping. Research highlights need for prevention and intervention.

Follow the Money: Oncology, Autoimmunity, Breast, Prostate Clinical Trials, T Cell Products, More

Multiple biotech companies raise significant funds for various medical advancements, including $600M for Symbiotic Capital targeting biotechnology, medical devices, diagnostics, and synthetic biology; $165M Series A for Third Arc Bio's multifunctional antibodies for oncology and autoimmunity; $144M Series B for Outpace Bio's AI-powered cell therapies for solid tumors; and others ranging from $126M for Halda Therapeutics' RIPTAC cancer therapies to $5M for Kano Therapeutics' targeted, non-viral DNA insertion technology.
© Copyright 2024. All Rights Reserved by MedPath